{"id":"NCT01610713","sponsor":"Jazz Pharmaceuticals","briefTitle":"An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis","officialTitle":"Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-05","primaryCompletion":"2002-07","completion":"2002-07","firstPosted":"2012-06-04","resultsPosted":"2012-09-19","lastUpdate":"2023-01-10"},"enrollment":154,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"GW-1000-02","otherNames":["Sativex"]}],"arms":[{"label":"GW-1000-02","type":"EXPERIMENTAL"}],"summary":"An open-label extension study in which patients with multiple sclerosis received GW-1000-02 \\[named Sativex® in Canada and also named Sativex® Oromucosal Spray\\] for four weeks in an open-label manner.","primaryOutcome":{"measure":"Change From Mean Part A Primary Impairment Visual Analogue Scale Score (After 6 Weeks) at the End of Four Weeks of Open-label Treatment (10 Weeks Total)","timeFrame":"End of Part A (week 6) - end of Part B (week 10 [4 weeks total open-label treatment])","effectByArm":[{"arm":"GW-1000-02 DB/OL","deltaMin":-5.41,"sd":24.2},{"arm":"Placebo DB/GW-1000-02 OL","deltaMin":-7.51,"sd":24.75}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":14},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["15327042","25475413"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":77},"commonTop":["Dizziness","Headache not otherwise specified","Nausea","Diarrhoea not otherwise specified","Somnolence"]}}